olaparib
merck,astrazeneca
['solo-1', 'brca', 'olaparib']
olaparib as 1st line maintenance tx improves clinically meaningful os in brcam ovca pts. most important also: median time to next treatment extended to 5 years from diagnosis (solo-1)
some more patients may be cured?
#esmo22 
??????????? ??? ????????. Passionate and perfectionist. Med Onc with special love to Gyn Onc and prostate cancer.